StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson TALVEY (talquetamab) by Quarter

TALVEY (talquetamab) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson TALVEY (talquetamab): 40.9% in Q3 2026, down 19.9 pts from a year earlier.

Latest, Q3 2026
40.9%
Period ended Sep 30, 2026
Change on a year earlier
-19.9 pts
60.8% in Q3 2025
History
7 quarters
Since Q1 2025
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“|| WW | 171 | 122 | 40.9 | 42.1 | (1.2)”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTALVEY (talquetamab) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 202640.9%-19.9 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 202663.3%+8.3 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 202676.7%+28.3 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 202575.8%–Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 202560.8%–Form 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 202555.0%–Form 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 202548.4%–Form 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗

Cite this data

StockData. (2026). Johnson & Johnson TALVEY (talquetamab) (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-talvey-rep-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.